Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
TheDane,
TY, that explains my poor assumption.
JH,
Perhaps it was, vague to me. How did you deduce that it was about P?
"cabel Wednesday, 02/28/18 01:33:01 PM
Re: None 0.010
Post #
219278
of 219374
Just wanted to share this from Leo,.. after I sent off an email to him asking him if we are close,...
Quote:
The trial is still blinded as the CRO is still "processing the data". There are many sites and many data points. We will update shareholders with top line results as soon as we receive and review the data. We projected to have the data this quarter.
Now back to my retirement preparation!"
In hindsight, I should have requested clarity from cabel.
RG,
How did you deduce that cabel post #219278 was about P? Djs's post #219275 and Williamsc's post #219277, immediately preceeding cabel's post(219278), was also specific to B.
Here is post #219278:
"cabel Wednesday, 02/28/18 01:33:01 PM
Re: None 0.010
Post #
219278
of 219374
Just wanted to share this from Leo,.. after I sent off an email to him asking him if we are close,...
Quote:
The trial is still blinded as the CRO is still "processing the data". There are many sites and many data points. We will update shareholders with top line results as soon as we receive and review the data. We projected to have the data this quarter.
Now back to my retirement preparation!"
I guess, after looking again, cabel's response could have been in trference to B or P, there is only one person who could figure that out...
Galera announced today BTD, 73 calendar days after they announced phase 2b results. Galera announced p2b results 187 calendar days after announcing enrollment completion. Ipix announced enrollment completion on 8/7/17 which was 206 calendar days ago(Galera announced results 187 days after enrollment completion). Results are clearly close, both by my back of a napkin analysis and cabel's correspondence with LE(Q1 2018).
My recolection is the same as yours. I was also looking for "leader".
Found it, 1/29/18 pr:"After a recent successful Phase 2 trial in Oral Mucositis (OM), the Company believes that it is the clear global leader in this area as it develops an easy-to-administer oral rinse medicine for the prevention of severe Oral Mucositis (SOM) in Head and Neck Cancer (HNC) patients receiving chemoradiation—analysts estimate this market could reach $1 billion in coming years."
http://www.ipharminc.com/press-release/2018/1/29/innovation-pharmaceuticals-brilacidin-franchise-anchored-in-three-clinical-indications-oral-mucositis-inflammatory-bowel-disease-and-serious-skin-infections-expands-into-dermatologic-diseases
Those are words of confidence, considering he has to be aware of Galera's recent 2b results(they share a common scientific advisor, Dr. Stephen Sonis).
You may be referring to this, from their 12/11/17 pr:
“The completion of the Phase 2 trial of Brilacidin-OM is a major milestone for the Company, particularly given the successful topline study results. In a broader context, these mid-phase study results represent a watershed moment in the management of OM, as there has been negligible prior innovation in safely mitigating the onset of the severest stages of the disease,” commented Leo Ehrlich, Chief Executive Officer at Innovation Pharmaceuticals. “We believe that we now occupy a leadership position with this drug candidate in the prevention and treatment of severe OM in Head and Neck Cancer patients. Considering the global unmet medical need in treating severe OM, we anticipate leveraging these promising data, both in securing potential partnership opportunities and establishing an early competitive market position. In combination with other promising clinical data on Brilacidin, we are building a strong case that our novel defensin-mimetic pipeline can safely address an array of diseases and conditions by showing meaningful clinical responses. We now look forward to discussing our plans with the FDA to best align and prepare for the expedient advancement of the Brilacidin-OM program.”
http://www.ipharminc.com/press-release/2017/12/11/innovation-pharmaceuticals-reports-positive-topline-results-from-phase-2-placebo-controlled-trial-of-brilacidin-for-the-prevention-of-oral-mucositis-in-head-and-neck-cancer-patients
Galera announced today BTD, 73 calendar days after they announced phase 2b results. Galera announced p2b results 187 calendar days after announcing enrollment completion. Ipix announced enrollment completion on 8/7/17 which was 206 calendar days ago(Galera announced results 187 days after enrollment completion). Results are clearly close, both by my back of a napkin analysis and cabel's correspondence with LE(Q1 2018).
"Quote:
The trial is still blinded as the CRO is still "processing the data". There are many sites and many data points. We will update shareholders with top line results as soon as we receive and review the data. We projected to have the data this quarter."
It's got be getting close if it tracks Galera progress:
Galera enrollment completed 6/15/17 vs 8/7/17 for ipix
Galera announced results on 12/18/17 vs tbd for ipix
Galera announces FDA BTD on 2/28/18
Galera # patients 233 vs. 61 for ipix
Galera # sites 61 vs. 16 for ipix
Galera # of primary outcome measures of 1 vs 2 for ipix
Galera # of secondary outcome measures of 7 vs 16 for ipix
Galera # of other outcome measures of 14 vs none for ipix
Evidently a phase 1 study: Brief Summary:
The purpose of the phase 1, GTO-003 clinical study is to determine the safety, tolerability and pharmacokinetics of a single dose of a new drug called GC4711 when given as an oral tablet. This study will compare capsules containing a liquid suspension of GC4711 when given orally to a similar drug called GC4419 which will be given as an intravenous infusion. This study will also assess the effect of food on GC4711.
https://clinicaltrials.gov/ct2/show/NCT03099824?term=gc4419&draw=2&rank=7
Sox,
We shall all learn shortly whether the "forward looking statements(and photos)" made by the company will pan out for B-up
I believe they shall succeed at one or more(B,P,K) for targeted indications, based on their Non Forward Statements(Michael Sullivan for example).
Perhaps the sentiment is
PP,
Pardon my ignorance, but why is the outcome you referenced a "scary thought" to you?
Thanks,
kfc
No one knows the final outcome, so to lighten things up, insert INNO(ipix abbreviated) in place of every reference to Scotland(and please, laugh,or at least smile(I'm a Libra:):).
Thanks Sox, informative and speaks to P's potential pending the 2b results.
My apologies to those exposed to my rant yesterday, as I was a bit riled and should have "bitten my tongue".
Are you out of here?
Why, if so?
Leo E called me back(thanks to a poster here) within a short period of time after my inquiry. He was very cordial. I requested a meeting to which he responded, being the last week of December, there would not be a full office. He conveyed the message to Dr Menon and he(Dr Menon) and I met a few days b4 new years.
Not able to reach LE, or anyone else, today.
My second attempt to call was today. My first, back in December, was not answered. Thanks to a poster on this mb, who communicated my desire for dialogue with the company, LE called me(back).
Jules, yes, that was the number I called in on and left messages with LE, JH(got SH), and the operator. Could not access AB.
Mike,
What does Bertolino start with?
I'll save you some key board time(you are a busy guy)TRY IT YOURSELF. IPIX phone# (978) 921-4125
Please enter the name of the party you are trying to reach, starting with last name first.
KarinCA, Georgejjl, or Septmike09,
Care to chime in?
"They're not going to give you non-public info of course."
But, what is so difficult answering/returning a phone call?
Think about this, according to their answering machine, their is no one employed there whose last name starts with B(don't my word for it, try it yourself. The message I received was "your party can not be identified".).
Hope you are right.
I left (4) messages with ipix today(SH & KM both successful, my first attempt to LE resulted in a response that his mailbox was full. the 2nd attempt for the operator(press 0) resulted in no one is available to take your call, the 3rd to SH resulted in me leaving a message, as did the 4th to KM).
Also left a message with one of their scientific advisors.
Like most on this board, one way or the other, I also have questions(which can not definitively be answered here).
IPIX-(978) 921-4125
Based on Scottwny's reply(#218803)https://investorshub.advfn.com/boards/read_msg.aspx?message_id=138802253, I wish I'd packed a D ring and harness with a short lanyard. Oh well, when the doors do open I'll hang on for dear life.
Musical chairs.
Ouch, you sunk his battleship!
I remember you, I was seated near you. Not sure how I ended up here in the undercarriage with the landing wheels, but at least we haven't crashed. Looking forward to a smooth landing....
Rdunn,
Instead of complaining full time here(all are entitled to gripe some, but....), why not call them directly and ask them, rather than anonymous posters. Innovation Pharmaceuticals phone # is (978) 921-4125.
I know which post you are referring to (your post preceding the one I am responding to), and must say it is curious.
OK, I'll bite, who's Norchi>(and what are you implying?).
TY
What is today's fair market share price, iyo.
SP 6 mos ago, 1 yr ago, 2 yrs ago, 4 yrs ago..., has never been hit on the high end? Has never hit on the low end(rhetorical question(beeter have been today), we need a tug boat to get us out of these doldrums and into the wind).
Pros – Reasons for having an SAB
The first three bullets align with my thinking (and my statement of wondering why n recent response from ipix's SA's.
https://lifescivc.com/2012/09/biotech-scientific-advisory-boards-what-works-what-doesnt/
Has Sonis(or other advisors) never been quoted, in not only an ipix pr, but bp's in general? I would think the more encouraged they are by results(it's close to their lives work), the more likely they'd be to pipe in(after being updated by the company sponsoring the endeavor).
Agree. I was hoping for a bit of a plug from Sonis or one of the advisor's covering B(P or K). No peeps for a while. Are they(advisors) kept apprised of developments? Hopefully Leo has not become a one-armed paper hanger.
$20B would certainly be nice, but that is a lot of dough. The attached link shows US Cos with the most available cash stored overseas and the percent overseas cash represents to their total cash. Some big names, including BP's.
https://www.axios.com/the-us-companies-with-the-most-cash-parked-overseas-1513388347-50edfdb5-863f-48fa-a99b-2dc7f3985227.html
Hope you're right.
Let's hope Leo and Co. prove Kingworthy!
clinicaltrials.gov/ct2/show/NCT02949388?term=innovation+pharmaceuticals&draw=2&rank=3
Edward Walters
clinicaltrials.gov/ct2/results?term=innovation+pharmaceuticals&rank=3#rowId2
Line item 3.
George,
Edwards is the only tie left(as far as I know) between Polymedix and ctix(ipix). I would agree with your statement that Leo, Menon, and Bertolino should be credited, but let's not put the cart before the horse(Edwards was pushing the "B franchise well before LE, KM, or AB, while at Polymedix).
George, you state "There's a reason for those "approaching 20" CDA's, and that is Leo, Dr. Menon and Dr. Bertolino, et. al."
That is backward thinking in my view. I would declare There's a reason for those "approaching 20" CDA's, and that is Edward Walters et. al at ipix.